TCM
PCRX icon

Tributary Capital Management’s Pacira BioSciences PCRX Stock Holding History

Tributary Capital Management’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-251,288
Closed -$7.19M – 213
2024
Q2 		$7.19M Buy
251,288
+420
+0.2% +$12K 0.6% 61
2024
Q1 		$7.33M Buy
250,868
+8,863
+4% +$272K 0.6% 62
2023
Q4 		$8.17M Buy
242,005
+59,593
+33% +$1.74M 0.69% 62
2023
Q3 		$5.6M Buy
182,412
+3,877
+2% +$140K 0.53% 61
2023
Q2 		$7.15M Sell
178,535
-3,370
-2% -$139K 0.64% 67
2023
Q1 		$7.42M Buy
181,905
+8,461
+5% +$337K 0.69% 65
2022
Q4 		$6.7M Sell
173,444
-8,523
-5% -$415K 0.67% 66
2022
Q3 		$9.68M Sell
181,967
-1,310
-0.7% -$72.8K 1.02% 53
2022
Q2 		$10.7M Sell
183,277
-5,230
-3% -$343K 1.06% 49
2022
Q1 		$14.4M Buy
188,507
+9,300
+5% +$620K 1.14% 42
2021
Q4 		$10.8M Sell
179,207
-11,069
-6% -$610K 0.81% 58
2021
Q3 		$10.7M Buy
190,276
+65,442
+52% +$3.77M 0.82% 58
2021
Q2 		$7.58M Buy
124,834
+5,186
+4% +$328K 0.57% 61
2021
Q1 		$8.39M Sell
119,648
-30,963
-21% -$2.21M 0.66% 59
2020
Q4 		$9.01M Buy
150,611
+11,208
+8% +$656K 0.65% 62
2020
Q3 		$8.38M Buy
+139,403
New +$8.1M 0.72% 57

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Tributary Capital Management's PCRX Position: Q3 2024 in Review

Tributary Capital Management sold out of Pacira BioSciences (PCRX) in Q3 2024, closing a stake of 251,288 shares — an estimated $7.19M sold.

Tributary Capital Management first reported a position in PCRX in Q3 2020 and held it in 16 quarters. The position peaked at $14.4M in Q1 2022. 239 funds tracked by Wall St. Rank hold PCRX as of Q3 2024.

  • Tributary Capital Management reported no remaining Pacira BioSciences position as of Q3 2024 after selling out during the quarter.
  • Tributary Capital Management sold 251,288 Pacira BioSciences shares in Q3 2024, an estimated $7.19M.
  • Tributary Capital Management first reported a position in Pacira BioSciences in Q3 2020 and held it in 16 quarters.
  • Tributary Capital Management's Pacira BioSciences position peaked at $14.4M in Q1 2022.
  • 239 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2024.

Based on Tributary Capital Management's 13F filing for Q3 2024, filed 24 Oct 2024.